In a study published in the British Medical Journal, researchers from the Mayo Clinic after examining more than 200 articles addressing the safety and efficacy of Avandia concluded that, "[a]uthors who had favourable views on the safety of rosiglitazone were more likely to have a financial conflict of interest with a pharmaceutical company than were authors who had unfavourable views." The study reported that nearly 90 percent of scientists who wrote positive articles, reviews or commentaries about Avandia had financial ties to London-based Glaxo.

These findings come in the wake of recent Senate Finance Committee report, "Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia" which detailed the lengths to which Glaxo, "GSK' went to preserve and promote Avandia. On February 18, 2010 Senators Grassley and Baucus called on the FDA to address their actions with respect to Avandia. The Senate's report and the Mayo study have reignited calls for the withdrawal of Avandia from the market.